Navigation Links
Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
Date:6/21/2010

Therapure Biopharma Inc. today announced an agreement under which Therapure will provide manufacturing services for ProChon Biotech, a specialty pharmaceutical company based in Israel with an executive management team based in Woburn, MA. Under the terms of the agreement, Therapure will provide services to support clinical manufacturing for one of ProChon’s products, which may be used for reconstructive surgery. The companies are also negotiating contracts for on-going manufacturing services, subject to the product achieving FDA approval. Financial terms were not disclosed.

Toronto, ON (PRWEB) June 21, 2010 -- Therapure Biopharma Inc. today announced an agreement under which Therapure will provide manufacturing services for ProChon Biotech, a specialty pharmaceutical company based in Israel with an executive management team based in Woburn, MA. Under the terms of the agreement, Therapure will provide services to support clinical manufacturing for one of ProChon’s products, which may be used for articular cartilage regeneration. The companies are also negotiating contracts for on-going manufacturing services, subject to the product achieving FDA approval. Financial terms were not disclosed.

ProChon Biotech Limited (Prochon) is a privately owned biotechnology company focused on providing products for articular cartilage regeneration. Prochon’s expertise in modulating the fibroplast growth factor (FGF) enables it to create more effective solutions for tissue regeneration.

“We are pleased to have been chosen by Prochon as its partner to provide clinical manufacturing services” said Thomas Wellner, President and CEO of Therapure. “Therapure has performed these services for a number of clients and has demonstrated market leading expertise.” continued Mr. Wellner.

“We believe that Therapure has the most relevant expertise for successful implementation of our manufacturing requirements.” said Patrick O’Donell, CEO of Prochon Inc.

About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

For more information, please visit: www.therapurebio.com

Company Contacts:

Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204

###

Read the full story at http://www.prweb.com/releases/biopharma/manufacturing/prweb4162674.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
2. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
3. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
4. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
5. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
6. Therapure Biopharma Inc. opens for business with first client contracts
7. Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
8. IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions
9. PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
10. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
11. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):